SciBase Holding has announced that the Board has appointed Pia Renaudin as the company’s Chief Executive Officer (CEO).
Simon Grant resigned from his position as CEO for personal reasons and will remain with the company until the end of October to fully support the transition.
Pia Renaudin is an exceptionally well-suited candidate to implement SciBase’s strategy in order to reach the company’s full potential, the company states. The board is convinced that she will help in creating shareholder value.
” I am very pleased to welcome Pia Renaudin as our new CEO. She has an extensive track record of developing and growing businesses and a broad international experience. She has built up businesses from scratch to multi-million SEK sales in the United States, a key component of our growth strategy. We believe that Pia is the right CEO to execute our strategy and to bring SciBase to the next level.” Furthermore, he added: “I would also like to take the opportunity and thank Simon Grant for his long-term dedication and for an excellent job done in positioning SciBase with the products and indications that will now take the company to the next phase. On behalf of the Board, we wish him personally all the best for his future endeavors,” says Tord Lendau, Chairman of the Board at SciBase.
Pia Renaudin
Pia Renaudin has extensive experience in the global Life Science and MedTech industries. She has spend over 20 year in leading positions in companies such as Senzime AB, Gilead Sciences, Stryker and AstraZeneca. Pia joins SciBase from Senzime AB, a Swedish MedTech Company listed on Nasdaq Stockholm main market, where she held the position of CEO from 2019 to 2023. During her tenure she significantly grew the sales, for instance in Q1-23 sales in Senzime grew by 161% with the US constituting the majority of the sales and growing by 215%.
“I am thrilled to be joining SciBase at this transformative stage, following the positive reimbursement news. I am looking forward to lead and expand SciBase to become a successful commercial entity for the benefit of patients and all other stakeholders in my new role as CEO. I am convinced we have a very exciting future with great growth potential ahead of us,” says Pia Renaudin.
Photo of Pia Renaudin: SciBase
